Pfenex Announces Positive Anthrax Vaccine Study Results

Go back to Pfenex Announces Positive Anthrax Vaccine Study Results

Pfenex (PFNX) Tops Q2 EPS by 4c

August 8, 2016 7:33 AM EDT

Pfenex (NYSE: PFNX) reported Q2 EPS of ($0.43), $0.04 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $3.1 million versus the consensus estimate of $2.55 million.

For earnings history and earnings-related data on Pfenex (PFNX) click here.

... More